The nanoparticle vaccine, NVX-CoV2373, containing trimeric S protein and Matrix-M1 adjuvant, was declared safe and effective based on phase-1–2 trial results, having elicited an immune response exceeding than that seen in COVID-19 convalescent serum [39]. The gene discussed is PROS1; the disease is COVID-19.